Synbio International Business Summary

Synbio International, Inc. (SYIN) is a diversified medical technology and health-focused company that has pivoted from its legacy food operations toward AI-driven medical diagnostics and nutraceuticals. The company generates revenue through the development and commercialization of clinically validated diagnostic tools, primarily leveraging its strategic alliance with FacialDx Inc. to market the NIMS™ (Non-invasive Medical Screening) platform. This AI-powered technology analyzes facial imagery to provide objective screening for mental health disorders such as Post-Traumatic Stress Disorder (PTSD) and Major Depressive Disorder (MDD). Its business segments are divided into AI Medical Diagnostics, which focuses on clinical and corporate wellness licensing, and a legacy Food Products division that markets meat-vegetable protein blends under the SoLean brand. Direct competitors include Ellipsis Health, Kintsugi, and Steakholder Foods; Synbio distinguishes itself by integrating decades of psychological research into a mobile-accessible, objective physiological analysis tool currently undergoing proof-of-concept clinical trials in Australia. The leadership team is led by Chairman and CEO Giacinto Claudio Solitario, a veteran of the biotech sector who previously served as a director for the ASX-listed Medibio and founded Invatec Health. In late 2025, the company significantly bolstered its executive ranks by appointing Desiree Cain, a CPA with over 25 years of corporate finance experience, as Chief Financial Officer, and Dr. Nick Vatakis as Medical Director. Dr. Vatakis is a board-certified psychiatrist and a prominent clinical researcher who has served as a principal investigator on more than 200 clinical trials, bringing critical scientific pedigree to the company’s diagnostic validation efforts. The board of directors is further supported by a strategic partnership with FacialDx, which includes reciprocal share purchase and warrant agreements designed to align long-term commercial interests following potential FDA regulatory milestones.